Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR® platform through Molecular Profiling Integration (MPI). This integration will provide 4,200 providers across 800 community-based cancer care locations with direct access to Tempus' suite of testing options within their workflow. The system enables electronic ordering, tracking, and result delivery through a unified ordering system, reducing administrative burden. The integration includes access to various Tempus tests including xT, xR, xF/xF+, xG/xG+ Ambry, and xM/xM, along with AI-enabled algorithmic add-on tests.
Tempus has published a study in JAMA Network Open demonstrating the advantages of combining RNA and DNA sequencing in advanced non-small cell lung cancer (NSCLC) treatment. The retrospective study of over 5,500 NSCLC patients revealed that concurrent RNA- and DNA-based next-generation sequencing detected more actionable structural variants than DNA sequencing alone. 8.8% of patients showed at least one actionable variant, with the combined approach increasing variant detection by 15.3% and more than doubling the identification of rare structural variants compared to DNA sequencing alone.
Tempus AI (NASDAQ: TEM) announced nine abstracts accepted for presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting in November 2024. Key highlights include two poster presentations: one validating a novel multi-omic algorithm for predicting immune checkpoint inhibitor (ICI) treatment outcomes using the Immune Profile Score (IPS), and another analyzing the cost-effectiveness of molecular biomarkers combined with CT imaging for treatment response monitoring. The second study, involving 4,147 cancer patients, demonstrated significant cost savings when using molecular biomarkers alongside CT imaging, particularly in small cell lung cancer treated with ICI-chemotherapy.
Tempus announced the clinical launch of its Immune Profile Score (IPS) algorithmic test, a multimodal biomarker for adult patients with stage IV and metastatic pan-solid tumors who are candidates for immune checkpoint inhibitor therapy. The validation study, involving 1,600 patients with 19 different solid tumor types, showed that IPS-High patients were more likely to have better overall survival while receiving ICI-based therapy compared to IPS-Low patients (HR 0.45). The test calculates a score from 0-100 and provides IPS-Low or IPS-High classification, operating independently of tumor mutational burden, PD-L1 immunohistochemistry, and microsatellite instability status.
Tempus reported Q3 2024 financial results and announced the acquisition of Ambry Genetics for $600M ($375M cash, $225M shares). Revenue grew 33% YoY to $180.9M, with data services revenue up 64.4% and genomics unit growth of 23.9%. The company posted a net loss of $(75.8M), including $22.2M in stock compensation. Ambry Genetics is expected to generate >$300M revenue and >$40M EBITDA in 2024. The acquisition expands Tempus' testing capabilities in hereditary cancer screening and new disease categories. Full-year 2024 guidance maintains at ~$700M revenue.
Tempus AI (NASDAQ: TEM) announced it will report its third quarter 2024 financial results on Monday, November 4, 2024. The earnings conference call is scheduled for 4:30 p.m. ET on the same day, replacing the previously scheduled November 7 call. CEO Eric Lefkofsky and CFO Jim Rogers will lead the call, which will be accessible via webcast through Tempus' Investor Relations website or by phone using provided dial-in numbers.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024. The earnings conference call will be held at 4:30 p.m. ET, featuring CEO Eric Lefkofsky and CFO Jim Rogers. The call will be accessible through Tempus' Investor Relations website's events page, with both domestic and international dial-in options available.
Tempus AI, Inc. (NASDAQ: TEM) announces an expanded collaboration with Takeda to enhance oncology research and development. The partnership leverages Tempus' de-identified multimodal datasets and biological modeling capabilities to advance Takeda's cancer therapeutics pipeline. Takeda researchers will use Tempus' analytics platform, Lens, to access de-identified patient records and AI-enabled tools.
The collaboration includes a multi-phase biological modeling project using one of the world's largest repositories of patient-derived tumor organoids. Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications to evaluate preclinical candidates. This approach aims to enhance drug effectiveness prediction and guide early candidate prioritization.
Initial work has already yielded research to be presented at an upcoming medical congress, demonstrating the potential of this data-first approach in accelerating insights for drug development.
Tempus AI (NASDAQ: TEM) announced four abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The presentations include:
1. An oral presentation on the impact of AI in clinical trial screening and enrollment.
2. A poster on using circulating tumor DNA (ctDNA) to monitor treatment response in patients treated with tyrosine kinase inhibitors.
3. A poster on comprehensive genomic profiling for targeted therapy in advanced lung cancer patients.
4. A poster on the impact of RAS and BRAFV600E mutations on the tumor immune microenvironment in colorectal cancers.
These presentations showcase Tempus' commitment to leveraging AI and data to advance precision medicine and improve patient outcomes in oncology.
Tempus AI, Inc. (NASDAQ: TEM) has launched the beta version of olivia, an AI-enabled personal health concierge app for patients. This innovative app aims to empower individuals to manage their health data holistically. olivia uses generative AI to provide personalized support, offering features such as:
- Seamless connection with healthcare providers
- Comprehensive patient profile creation
- Appointment preparation assistance
- Health monitoring tools
The app addresses the challenge of managing healthcare data across multiple providers and specialties, offering users a centralized platform to organize and access their health information. Tempus CEO Eric Lefkofsky emphasized that olivia leverages the company's investments in AI and multimodal healthcare data aggregation to benefit patients directly.